X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Patent (115) 115
Journal Article (85) 85
Conference Proceeding (12) 12
Publication (10) 10
Magazine Article (3) 3
Book Review (2) 2
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (64) 64
buttons, pins, buckles, slide fasteners, or the like (42) 42
haberdashery (42) 42
jewellery (42) 42
testing (32) 32
physics (31) 31
chemistry (30) 30
measuring (30) 30
index medicus (29) 29
metallurgy (29) 29
peptides (28) 28
organic chemistry (26) 26
performing operations (26) 26
transporting (26) 26
investigating or analysing materials by determining theirchemical or physical properties (25) 25
humans (24) 24
hygiene (22) 22
medical or veterinary science (22) 22
specific therapeutic activity of chemical compounds ormedicinal preparations (21) 21
article (13) 13
mechanical metal-working without essentially removingmaterial (12) 12
melanoma (12) 12
punching metal (12) 12
cell line, tumor (11) 11
cancer (10) 10
proto-oncogene proteins b-raf - antagonists & inhibitors (10) 10
animals (9) 9
beer (9) 9
biochemistry (9) 9
enzymology (9) 9
female (9) 9
melanoma - drug therapy (9) 9
mice (9) 9
microbiology (9) 9
mutation or genetic engineering (9) 9
spirits (9) 9
tumors (9) 9
vinegar (9) 9
wine (9) 9
biochemistry & molecular biology (8) 8
melanoma - genetics (8) 8
preparations for medical, dental, or toilet purposes (8) 8
proto-oncogene proteins b-raf - genetics (8) 8
working or processing of sheet metal or metal tubes, rods orprofiles without essentially removing material (8) 8
male (7) 7
mutation (7) 7
oncology (7) 7
adult (6) 6
analysis (6) 6
cell biology (6) 6
compositions thereof (6) 6
culture media (6) 6
drug resistance, neoplasm - drug effects (6) 6
melanoma - pathology (6) 6
microorganisms or enzymes (6) 6
middle aged (6) 6
propagating, preserving or maintaining microorganisms (6) 6
research (6) 6
targeted therapy (6) 6
vemurafenib (6) 6
braf (5) 5
care and treatment (5) 5
electricity (5) 5
fixed constructions (5) 5
immune checkpoint blockade (5) 5
in-vivo (5) 5
protein (5) 5
protein kinase inhibitors - therapeutic use (5) 5
aged (4) 4
angiogenesis (4) 4
antineoplastic agents - therapeutic use (4) 4
base sequence (4) 4
building (4) 4
ceilings (4) 4
circuit noise (4) 4
compositions or test papers therefor (4) 4
condition-responsive control in microbiological orenzymological processes (4) 4
conveying (4) 4
diagnosis (4) 4
drug resistance (4) 4
drug resistance, neoplasm - genetics (4) 4
electromagnetic compatibility (4) 4
expression (4) 4
floors (4) 4
general building constructions (4) 4
handling thin or filamentary material (4) 4
heating (4) 4
immunotherapy (4) 4
indoles - pharmacology (4) 4
insulation or other protection of buildings (4) 4
kinases (4) 4
machine tools (4) 4
measuring or testing processes involving enzymes, nucleicacids or microorganisms (4) 4
mek (4) 4
melanoma - metabolism (4) 4
metal-working not otherwise provided for (4) 4
metastasis (4) 4
metastatic melanoma (4) 4
mice, inbred c57bl (4) 4
mice, nude (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Research, ISSN 0008-5472, 08/2011, Volume 71, Issue 15, pp. 5067 - 5074
(V600E)B-RAF mutation is found in 50% to 60% of melanomas, and the novel agents PLX4032/vemurafenib and GSK2118436 that inhibit the (V600E)B-RAF kinase achieve... 
Apoptosis - drug effects | Humans | Multiprotein Complexes | Neoplasm Proteins - physiology | Recombinant Fusion Proteins - physiology | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Platelet-Derived Growth Factor beta - genetics | Quinolines - pharmacology | Mechanistic Target of Rapamycin Complex 1 | Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Spheroids, Cellular - drug effects | MAP Kinase Kinase Kinases - antagonists & inhibitors | Proteins - physiology | Transcription Factors - physiology | Receptor, Platelet-Derived Growth Factor beta - physiology | Morpholines - pharmacology | Transcription Factors - antagonists & inhibitors | Imidazoles - pharmacology | Proto-Oncogene Proteins c-akt - physiology | Melanoma - pathology | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Point Mutation | Vemurafenib | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Phosphatidylinositol 3-Kinases - physiology | Signal Transduction - physiology | TOR Serine-Threonine Kinases | Drug Resistance, Neoplasm - physiology | Proteins - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects | Drug Screening Assays, Antitumor | Index Medicus | vemurafenib | targeted therapy | melanoma | AKT | B-RAF | acquired resistance
Journal Article
Nature, ISSN 0028-0836, 12/2010, Volume 468, Issue 7326, pp. 973 - 977
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 368 - 372
Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer(1,2). Here we show that targeted therapy with... 
CNS CELL-TYPES | MELANOMA | METASTASIS | MICROENVIRONMENT | TRANSLATIONAL PROFILING APPROACH | MULTIDISCIPLINARY SCIENCES | RAF INHIBITOR RESISTANCE | ACQUIRED-RESISTANCE | KINASE INHIBITORS | DRUG-RESISTANCE | CANCER CHEMORESISTANCE | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Clone Cells - drug effects | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Proto-Oncogene Proteins c-fos - deficiency | Adenocarcinoma - metabolism | Neoplasm Metastasis - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Proto-Oncogene Proteins c-akt - metabolism | Melanoma - metabolism | Tumor Microenvironment - drug effects | Cell Survival - drug effects | Melanoma - pathology | Down-Regulation - drug effects | Enzyme Activation - drug effects | Adenocarcinoma - drug therapy | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Cell Movement - drug effects | Lung Neoplasms - secretion | Melanoma - secretion | Animals | Clone Cells - pathology | Metabolome - drug effects | Signal Transduction - drug effects | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adenocarcinoma - secretion | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Pharmaceutical research | Care and treatment | Oncology, Experimental | Dosage and administration | Research | Drug therapy | Drug resistance | Antineoplastic agents | Tumors | Cancer | Melanoma | Mutation | Metastasis | Kinases | Cancer therapies | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2009, Volume 106, Issue 50, pp. 21288 - 21293
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2012, Volume 18, Issue 8, pp. 1239 - 1247
The inactivation of the p53 tumor suppressor pathway, which often occurs through mutations in TP53 (encoding tumor protein 53) is a common step in human... 
MEDICINE, RESEARCH & EXPERIMENTAL | N-RAS | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUMOR-SUPPRESSOR ACTIVITY | STAPLED P53 | BRAF | MALIGNANT-MELANOMA | P53 PATHWAY | CELL-DEATH | CELL BIOLOGY | BREAST-CANCER | METASTATIC MELANOMA | IN-VIVO | Up-Regulation | Proto-Oncogene Proteins c-mdm2 - genetics | Tumor Suppressor Protein p53 - antagonists & inhibitors | Apoptosis - drug effects | Humans | Neoplasm Proteins - physiology | Gene Expression Regulation, Neoplastic | Recombinant Fusion Proteins - physiology | Skin Neoplasms - chemistry | Male | Melanocytes - metabolism | Neoplasm Proteins - antagonists & inhibitors | Cell Line, Tumor - transplantation | Proto-Oncogene Proteins - biosynthesis | Tumor Suppressor Protein p53 - physiology | Cell-Penetrating Peptides - pharmacology | Nuclear Proteins - biosynthesis | Female | Antineoplastic Agents - pharmacology | Neoplasm Proteins - genetics | Nuclear Proteins - genetics | Cell Line, Tumor - metabolism | Melanoma - chemistry | Proto-Oncogene Proteins c-mdm2 - biosynthesis | Proto-Oncogene Proteins - antagonists & inhibitors | Tumor Stem Cell Assay | Membrane Proteins - genetics | Neoplasm Proteins - biosynthesis | Melanoma, Experimental - etiology | Mice, Inbred C57BL | Mice, Transgenic | Proto-Oncogene Proteins - genetics | Melanoma - pathology | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Melanoma, Experimental - genetics | GTP Phosphohydrolases - genetics | Keratinocytes - metabolism | Mice, Nude | Nuclear Proteins - antagonists & inhibitors | Proto-Oncogene Proteins - physiology | Signal Transduction - physiology | Mice | Nuclear Proteins - physiology | Drug Resistance, Neoplasm - physiology | Drug Resistance, Neoplasm - drug effects | Care and treatment | Gene mutations | Melanoma | Diagnosis | Research | Gene expression | Identification and classification | Skin cancer | Proteins | Cell growth | Mutation | Cell cycle | Index Medicus
Journal Article
Cancer Science, ISSN 1347-9032, 09/2019, Volume 110, Issue 9, pp. 2941 - 2959
A sensitive and specific diagnosis biomarker, in principle scalable to most cancer types, is needed to reduce the prevalent cancer mortality. Meanwhile, the... 
Hsp90α | ADAM | PKC | pan‐cancer biomarker | heterogeneity | Heat shock proteins | Liver cancer | Diagnosis | Analysis | Cancer | Antigens | Protein kinase C | Clinical trials | FDA approval | Exosomes | Kinases | Western blotting | Studies | Accuracy | Hospitals | Proteomics | Biomarkers | Enzyme-linked immunosorbent assay | Index Medicus | ADAM10 | Original | PKCγ
Journal Article
Nature Chemical Biology, ISSN 1552-4450, 01/2019, Volume 15, Issue 1, pp. 42 - 50
Expression of programmed cell death 1 (PD-1) ligand 1 (PD-L1) protects tumor cells from T cell-mediated immune surveillance, and immune checkpoint blockade... 
HIV-1 NEF | APOPTOSIS | PROTEIN | DISRUPTION | SELECTIVE DEGRADATION | STABILIZATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | COMPLEXES | IDENTIFICATION | KNOCKDOWN | EXPRESSION | PD-1 protein | Peptides | Tumor cells | Toxicity | Lysosomes | Cytotoxicity | Immunosurveillance | Lymphocytes T | Degradation | Depletion | Immune checkpoint | Cell death | Lymphocytes | PD-L1 protein | Tumors | Apoptosis | Index Medicus
Journal Article
IEEE Transactions on Electromagnetic Compatibility, ISSN 0018-9375, 02/2005, Volume 47, Issue 1, pp. 10 - 16
Journal Article
Nature, ISSN 0028-0836, 12/2011, Volume 480, Issue 7377, pp. 387 - 390
Journal Article
Cancer Discovery, ISSN 2159-8274, 01/2014, Volume 4, Issue 1, pp. 80 - 93
Journal Article